Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Moderna to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
Experimental mRNA Vaccine Hints at Potential Against Glioblastoma
https://www.cancer.gov/news-events/cancer-currents-blog/2024/glioblastoma-mrna-vaccine-layered-nanoparticle
Bird flu virus infection is usually diagnosed by collecting a swab from the upper respiratory tract (nose or throat) of the sick person.
How is bird flu being tested
To determine its existence
Melanoma cancer vaccine results “extremely impressive”
The first vaccine treatment for the form of skin cancer usually caused by sun damage could halve the risk of patients dying or the disease returning, according to early trial results.
Researchers led by a team at New York University combined a vaccine using the same mRNA technology as many COVID jabs with an established immunotherapy called pembrolizumab. It was given to patients after they had surgery to remove stage 3 or stage 4 melanoma.
After three years, 75% of those who had the vaccine and pembrolizumab were still cancer-free, compared to 56% of people who only received pembrolizumab.
Iain Foulkes, our executive director of research and innovation explained that the results “show positive signs of the mRNA vaccine’s long-lasting effectiveness”, although larger and longer trials are still needed.
Unlike traditional vaccines, which are used to prevent disease, cancer vaccines are used to treat cancers. The vaccine used in this trial, mRNA-4157 (created by Moderna), is different for every patient. Scientists personalise it to help people’s immune system identify their specific cancer cells. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, supports this by effectively taking the brakes off of immune cells called T cells.
Speaking to journalists at ASCO, Swanton called the results “extremely impressive”.
“The new vaccine approach is another piece of the puzzle that will allow more patients to be cured, hopefully, or fewer patients to suffer disease relapse. Ultimately it will contribute to survival rates improving continually over the next decades and more.”
Through fear
And dominance
Without knowing
Its ramifications
If so
In what form
Shades of
Jussie Smollett
Do viruses exist
If he works for the government, why is he asking for donations?
Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR
https://www.labiotech.eu/in-depth/bridge-rna-gene-editing/
‘It’s Going to Be Catastrophic’: Why the Next Pandemic Will Be Worse Than COVID
https://www.dailysignal.com/2024/07/08/chinas-covid-deception-cost-us-18-trillion-1-1-million-lives/
$NOVAX
It's the way it's been done
Since the old days
The Reach
Be afraid
But we can help
No worries
Bird flu spread to cows takes 'dangerous' step towards infecting humans through respiration, scientists warn
https://news.sky.com/story/bird-flu-spread-to-cows-takes-dangerous-step-towards-infecting-humans-through-respiration-scientists-warn-13175177
Japan to ban MRNA
As turbo cancers among vaxxed
Skyrocketing
Turbo cancers are exploding among the vaccinated according to Japan’s leading oncologist who has slammed the mainstream media and Big Pharma in the West for covering up the extent of the medical crisis engulfing the world.
Prof. Emeritus Dr. Masanori Fukushima was ordered by the Japanese government to investigate why excess deaths skyrocketed in Japan in recent years.
His findings were conclusive: mRNA has destroyed immune systems and opened a Pandora’s box of autoimmune diseases, neurodegenerative diseases, cancer, and infections.
The Professor has a dire warning for those in the West – do not listen to mainstream media and Big Pharma as they are not engaged in science, but rather a eugenics experiment, and they have proven themselves to be enemies of the people.
Mitsubishi Tanabe Pharma will co-promote MRNA’s vaccines_in Japan:
https://www.accesswire.com/viewarticle.aspx?id=886055&lang=en
Financial terms of the co-promotion have not been disclosed.
Don't see the free advertising like before
Will this affect the bottom line
What could happen
Moving forward
Would depend on what's being hacked
Has nothing to do with health
What about clinicals
If this is major test
Sounds fishy
In a 153-page written ruling on Tuesday, Mr Justice Meade concluded one of the European Moderna patents, labelled EP565, was “invalid”.
But the judge said a different patent, called EP949, was “valid” and was infringed by Pfizer and BioNTech.
A Moderna statement said: “We are pleased that the UK High Court recognised the innovation of Moderna scientists by confirming the validity and infringement of the EP949 patent and that (the) defendants were not entitled to use Moderna’s patented technology for any infringing activity after March 7 2022.
https://www.standard.co.uk/news/crime/pfizer-moderna-high-court-netherlands-germany-b1168104.html
The article is behind a paywall—can you paraphrase the key points? TIA
Looking for the Best Health Hacks- Try Vaccines "anti-vax"
https://www.scientificamerican.com/article/vaccines-are-the-safest-health-hack/
Moderna secures partial victory in Covid vaccine legal fight
https://www.ft.com/content/c57bc08f-50b3-42ef-ad44-4d592b189ce7
Scientists wary of bird flu pandemic 'unfolding in slow motion'
"It almost seems like a pandemic unfolding in slow motion," said Scott Hensley, a professor of microbiology at the University of Pennsylvania. "Right now, the threat is pretty low ... but that could change in a heartbeat."
https://www.reuters.com/business/healthcare-pharmaceuticals/scientists-wary-bird-flu-pandemic-unfolding-slow-motion-2024-07-01/
10 clinical trials to watch in the second half of 2024
COMPANY: Moderna
DISEASE: Cytomegalovirus
TREATMENT TYPE: mRNA Vaccine
There are no vaccines for cytomegalovirus, or CMV.
Success would also open up the potential of a product analysts think could eventually generate more than $3 billion in peak yearly sales.
https://www.biopharmadive.com/news/biotech-10-clinical-trials-watch-2024-second-half/720005/
Making another buy call at this level
8+ billion cash
today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).
https://investors.modernatx.com/news/news-details/2024/Moderna-Receives-Project-Award-through-BARDAs-Rapid-Response-Partnership-Vehicle-Consortium-to-Accelerate-Development-of-mRNA-based-Pandemic-Influenza-Vaccine/default.aspx
Combined COVID-flu vaccines are coming: Moderna jab clears major test
https://www.nature.com/articles/d41586-024-02121-1
EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)
https://investors.modernatx.com/news/news-details/2024/EMA-Committee-For-Medicinal-Products-For-Human-Use-Adopts-Positive-Opinion-Recommending-Marketing-Authorization-Of-Modernas-RSV-Vaccine-mRESVIAR/default.aspx
Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
Lin Guey, PhD, Chief Scientific Officer of Therapeutics Research Ventures and Biotherapeutics at Moderna, stated, "We are thrilled with the significant progress we've made in advancing in vivo CAR-M therapies alongside Carisma. We eagerly anticipate further development of the nominated candidate for patients with solid tumors, and we look forward to continued success as we develop additional in vivo CAR-M together to bring new therapies to patients with HCC and other cancers."
The in vivo CAR-M program targeting GPC3 is being developed under the 2022 strategic collaboration agreement between Carisma and Moderna to discover, develop, and commercialize in vivo engineered CAR-M therapeutics for the treatment of cancer. In addition to this program, Moderna has nominated four undisclosed oncology research targets under the collaboration. Carisma is responsible for the discovery and optimization of development candidates, while Moderna will lead the development and commercialization of resulting therapeutics.
https://ir.carismatx.com/news-releases/news-release-details/carisma-therapeutics-announces-nomination-first-vivo-car-m
RNA Vaccines For Cancer $$$$$$$$$$$$
https://www.science.org/content/blog-post/rna-vaccines-cancer
What is bird flu
And how did it cross over
To cows
Get it yet
It's all a mind game
Nice digs! (eom)
Moderna offers a sneak peek inside of its new Kendall Square headquarters
https://www.bostonglobe.com/2024/06/26/business/moderna-headquarters/
Followers
|
175
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
13522
|
Created
|
12/10/18
|
Type
|
Free
|
Moderators DewDiligence Vexari axelvento |
2021 was a year of monumental impact and change for Moderna
Moderna entered 2021 with a strong cash position of approximately $5.25 billion. We have used this capital to invest in R&D and scale our development pipeline and manufacturing capabilities to maximize our impact on human health.
As we close our books for 2021, the company’s cash, cash equivalents and investments as of December 31, 2021, were more than $17 billion. We now have the resources to scale our investments and do even more to positively impact human health with mRNA medicines. This is just the beginning.
.
https://www.modernatx.com/newsroom/our-blog-coding-region/moderna-2021-shareholder-letter
Moderna is entering 2022 with a remarkable team poised to continue advancing mRNA vaccines and therapeutics into new areas for patients. We have a clear and exciting strategic path to do so, and a strong cash position.
Priority two is to go after the most important latent viruses and develop first-in-class vaccines against them. We want to protect our fellow human beings from suffering from the long-term damage caused by these viruses. Too many people have the quality of their health impacted because decades before, they were infected with a latent virus. We envision a world where vaccines against all the most important latent viruses are available to all.
Priority three is to bring to market therapeutics based on mRNA-encoded proteins, like our current pipeline in oncology, cardiology, rare genetic diseases and autoimmune diseases.
Priority four is to bring to market innovative therapeutics based on mRNA-encoded gene editing enzymes.
Moderna expects to enroll approximately 34,000 participants in multiple countries
RSV is a leading cause of severe respiratory illness in older adults (65+) and young children; there is no approved vaccine to prevent RSV
RSV illness in older adults results in an estimated $3 billion in annual medical costs in the U.S. each year
NOVEMBER, 18, 2021
https://investors.modernatx.com/news/news-details/2021/Moderna-Announces-First-Participant-Dosed-in-Phase-2-3-Study-of-its-mRNA-Respiratory-Syncytial-Virus-RSV-Vaccine/default.aspx
MODERNA ANNOUNCES POSITIVE DATA FROM PHASE 2 STUDY OF MRNA VEGF-A THERAPEUTIC IN PATIENTS UNDERGOING CORONARY ARTERY BYPASS GRAFTING SURGERY
Approval based on a comprehensive submission package including efficacy and safety data approximately six months after second dose
SPIKEVAX has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel
807 million doses of Moderna's COVID-19 vaccine shipped globally in 2021; approximately 25% of those doses shipped to low- and middle-income countries
https://investors.modernatx.com/news/news-details/2022/Moderna-Receives-Full-U.S.-FDA-Approval-for-COVID-19-Vaccine-Spikevax/default.aspx
Q4 2021 revenues of $7.2 billion; GAAP net-income of $4.9 billion and GAAP diluted EPS of $11.29
Full year 2021 revenues of $18.5 billion; GAAP net-income of $12.2 billion and GAAP diluted EPS of $28.29
Moderna increased its 2022 signed advance purchase agreements to approximately $19 billion, with additional signed options of approximately $3 billion; numerous discussions ongoing with governments for the fall of 2022 and 2023
Moderna received full U.S. FDA approval for COVID-19 vaccine, Spikevax
Moderna announces new bivalent booster candidate (mRNA-1273.214) combining Omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273)
Company now has 44 programs in development
Moderna announces a new $3 billion share repurchase plan
https://investors.modernatx.com/news/news-details/2022/Moderna-Reports-Fourth-Quarter-and-Fiscal-Year-2021-Financial-Results-and-Provides-Business-Updates/default.aspx
Facility to manufacture drug substance with opportunity for fill/finish and packaging capabilities
Moderna investing up to $500 million to produce up to 500 million doses each year for the African continent
Moderna will invest in building mRNA capabilities in Africa
https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Memorandum-of-Understanding-with-the-Government-of-the-Republic-of-Kenya-to-Establish-its-First-mRNA-Manufacturing-Facility-in-Africa/default.aspx
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |